Fast Five Quiz: Acute Coronary Syndrome

Yasmine S. Ali, MD


May 17, 2023

Patients with moderate- or high-risk ACS should receive an early, invasive approach that includes concomitant antithrombotic therapy, including aspirin and clopidogrel as well as unfractionated heparin or low-molecular-weightheparin (eg, dalteparin, enoxaparin, nadroparin), intravenous platelet glycoprotein IIb/IIIa complex blockers (eg, tirofiban, eptifibatide), and a beta-blocker. Early revascularization is the goal.

Low-risk patients with NSTEMI ACS should undergo further follow-up with biomarkers and clinical assessment. Intermediate-risk NSTEMI ACS patients should undergo further diagnostic assessment quickly to determine their appropriate risk category.

Learn more about approaches to treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.